Table Graph
      published meta-analysis   sensitivity analysis   studies

casirivimab/imdevimab (Ronapreve) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.75[0.60; 0.94]RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021233%4,350moderatenot evaluable deathsdetailed resultsRECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.75[0.60; 0.94]RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021233%4,350moderatenot evaluable death or ventilationdetailed resultsRECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] 0.79[0.65; 0.95]RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021234%4,280moderatenot evaluable hospital dischargedetailed resultsRECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] 1.24[1.05; 1.47]RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021229%4,350moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-19 23:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 771 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons